Medicenna Therapeutics Corp. is a clinical-stage biotech company that discovers and develops targeted immunotherapies for the treatment of oncology and auto-immune diseases. Their innovative platform combines antibody-drug conjugates (ADCs) with cytokines to create powerful therapies that selectively target and destroy cancer cells while minimizing harm to healthy cells. With a robust pipeline of products in development, Medicenna Therapeutics Corp. is poised for significant growth in the biotech industry.
